Welcome to our dedicated page for Envoy Medical SEC filings (Ticker: COCHW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Envoy Medical, Inc. filings document the public-company disclosures of a hearing health medical technology issuer with Class A common stock and Nasdaq-listed redeemable warrants under COCHW. Form 8-K reports include results of operations and financial condition, board and committee appointments, changes in the company’s certifying accountant, and related audit disclosures.
Proxy filings describe annual meeting proposals, director elections, independent auditor ratification, advisory executive compensation votes, amendments to the company’s equity incentive and employee stock purchase plans, and warrant or share-issuance matters under Nasdaq rules. The filing record also identifies Envoy Medical as an emerging growth company and discloses governance, capital-structure and risk-related subjects tied to its implantable hearing technology business.
Kantor Susan reported open-market purchase transactions in a Form 4 filing for COCH. The filing lists transactions totaling 249,990 shares at a weighted average price of $0.40 per share. Following the reported transactions, holdings were 57,690 shares.
BRYNELSEN CHARLES reported open-market purchase transactions in a Form 4 filing for COCH. The filing lists transactions totaling 2,600,000 shares at a weighted average price of $0.40 per share. Following the reported transactions, holdings were 600,000 shares.
Lucas Brent T. reported open-market purchase transactions in a Form 4 filing for COCH. The filing lists transactions totaling 162,500 shares at a weighted average price of $0.40 per share. Following the reported transactions, holdings were 37,500 shares.
TAYLOR GLEN A reported open-market purchase transactions in a Form 4 filing for COCH. The filing lists transactions totaling 48,750,000 shares at a weighted average price of $0.40 per share. Following the reported transactions, holdings were 11,250,000 shares.
Envoy Medical stockholder Glen A. Taylor filed an amended Schedule 13D to update his ownership after a February 2026 investment. He purchased 18,750,000 shares of Class A Common Stock together with Series A-1 Warrants for 11,250,000 shares and Series A-2 Warrants for 18,750,000 shares at a combined price of $0.40 per share and accompanying warrants, for an aggregate $7,500,000 funded with personal funds.
The common warrants have a $0.40 exercise price and become exercisable after stockholder approval of the warrant share issuance, with Series A-1 Warrants expiring up to 24 months after that approval (or earlier upon Milestone 1) and Series A-2 Warrants up to 60 months (or earlier upon Milestone 2). As of February 12, 2025, he is treated as beneficially owning 68,909,614 shares of Class A Common Stock, or 84.8% of the class, based on 76,881,110 shares outstanding immediately following the company’s offering, including the warrant shares. On the same date, he directly holds 29,040,049 outstanding shares, or 37.7% of those outstanding shares.
Envoy Medical, Inc. completed an upsized public offering that raised approximately $30.0 million in gross proceeds by selling an aggregate of 75,000,000 shares of Class A common stock (or pre-funded warrants in lieu) plus milestone-linked Series A-1 and Series A-2 warrants to purchase up to 120,000,000 additional shares.
The warrants carry a $0.40 exercise price and become exercisable after stockholder approval, with earlier expirations tied to FDA milestones for the company’s Acclaim cochlear implant. If fully exercised for cash, the warrants could bring in about $48.0 million more. Envoy plans to use the net proceeds for working capital and to fund its pivotal FDA clinical study, and it expects the financing to extend its cash runway into the second half of 2027.
Envoy Medical, Inc. reported that its Compensation Committee approved new stock option grants for its Chief Executive Officer and Interim Chief Financial Officer under the company’s 2023 Equity Incentive Plan.
On February 5, 2026, CEO Brent Lucas received options to purchase 200,000 shares of Class A common stock, and Interim CFO Robert Potashnick received options for 15,000 shares. Both grants have an exercise price of $0.53 per share, matching the closing price on the Nasdaq Capital Market on the award date. Twenty‑five percent of each grant vests after one year, with the remaining options vesting pro rata over the following 36 months, and each award has a 10‑year term.
Envoy Medical, Inc. received a Schedule 13G showing that Ayrton Capital LLC, Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B, and Waqas Khatri collectively report beneficial ownership of 2,457,963 shares of Class A common stock issuable upon exercise of warrants.
This position represents 7.87% of Envoy Medical’s common stock, calculated using 28,786,511 shares outstanding as of November 21, 2025, plus the warrant shares. The warrants are subject to a 9.99% beneficial ownership blocker, limiting how much of the company they can own at any time.
The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Envoy Medical. Voting and dispositive power over the 2,457,963 shares is reported as sole, with no shared power.
Envoy Medical, Inc. filed Amendment No. 2 to its Form S-1 registration statement as an exhibits-only update. The company states that the rest of the registration statement is unchanged and has been omitted from this amendment.
The amendment primarily adds or updates exhibits, including forms of warrants and a securities purchase agreement related to the planned offering, various employment and incentive plan documents, debt and forward purchase agreements, and an engagement letter with H.C. Wainwright & Co., LLC. Signature pages confirm authorization by the chief executive officer and directors.
Envoy Medical, Inc. reported that Interim CFO Robert Potashnick received a grant of stock options on February 5, 2026. The award covers 15,000 options to purchase Class A common stock at an exercise price of $0.53 per share, held directly.
The vesting schedule is structured so that 3,750 options vest on February 5, 2027, with the remaining 11,250 options vesting pro rata on the 5th of each month over the following 36 months. This aligns the Interim CFO’s compensation with longer-term company performance.